Scynexis (SCYX) Receivables (2013 - 2023)
Scynexis' (SCYX) quarterly Receivables came in at $19.4 million in Q4 2023, up 821.61% on a YoY basis from $2.1 million in Q4 2022, and down 10.17% quarter-over-quarter from $21.6 million in Q3 2023.
Analysis
Scynexis (SCYX) Receivables (2013 - 2023) Analysis & Trends
Scynexis (SCYX) has reported Receivables for 7 consecutive years, with $19.4 million the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Receivables rose 821.61% year-over-year to $19.4 million; the trailing twelve-month figure through Dec 2023 stood at $19.4 million (up 821.61% YoY), and the FY2023 full-year result was $19.4 million, up 821.61% from the prior year.
- Receivables retreated to $19.4 million in Q4 2023 per SCYX's latest filing, from $21.6 million in the prior quarter.
- Across five years, Receivables topped out at $21.6 million in Q2 2023 and bottomed at $29000.0 in Q3 2021.
- Historically, Receivables has averaged $7.0 million across 4 years, with a median of $2.2 million in 2022.
- The sharpest annual moves came in 2021 and 2022: Receivables tumbled 70.06% in 2021, then surged 8496.55% in 2022.
- Over 4 years, Receivables stood at $2.9 million in 2020, then sank by 70.06% to $861000.0 in 2021, then surged by 144.02% to $2.1 million in 2022, then surged by 821.61% to $19.4 million in 2023.
- According to Business Quant data, Receivables over the past three periods registered $19.4 million, $21.6 million, and $21.6 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 19.36 Mn |
| Sep 30, 2023 | 21.55 Mn |
| Jun 30, 2023 | 21.59 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 2.49 Mn |
| Jun 30, 2022 | 2.21 Mn |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 861,000.00 |
| Sep 30, 2021 | 29,000.00 |
| Dec 31, 2020 | 2.88 Mn |
| Mar 31, 2015 | 1.05 Mn |
| Dec 31, 2014 | 1.34 Mn |
| Sep 30, 2014 | 1.39 Mn |
| Jun 30, 2014 | 1.53 Mn |
| Mar 31, 2014 | 1.34 Mn |
| Dec 31, 2013 | 1.06 Mn |